REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
It can be difficult to know which sources of information you can trust. Learn more about finding credible vaccine information.
Updated 19 August 2021
Why does WHO recommend at this time, in June 2021, that vaccinating children is not a priority? When would their vaccination be prioritized? How is safety of these vaccines ensured? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
Do the current batch of approved vaccines protect us from the Delta variant? What is the level of protection? If you can still get infected even after being fully vaccinated, then why should we vaccinate? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
This guidance document provides basic principles for a spokesperson of any health authority on how to respond to vocal vaccine deniers. The suggestions are based on psychological research on persuasion, on research in public health, communication studies and on WHO risk communication guidelines.
This inter-agency guidance document aims to supplement the COVAX demand creation package for COVID-19 vaccines with key considerations for humanitarian contexts and marginalized populations with specific access and communication needs.
21 Sept.2021
updated version: 04/10/2021
Information about vaccine administration
Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, and for the fight against antimicrobial resistance.
WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vacci...nes in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need.
Gonococcal vaccine PPCs describe global public health goals for gonococcal vaccines and preferred parameters pertaining to vaccine indications and target populations, safety and efficacy considerations, and immunization strategies.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so...cial disruption and economic consequences of COVID-19, curtail the emergence of new SARS-CoV-2 variants of concern (VOCs) and ultimately control the pandemic.
more
News Release 11 april 2022
29 April 2022
What are the new vaccines in the pipeline? What are the challenges to turning vaccines into vaccination ? What timelines can we expect for future vaccines? WHO’s Dr Katherine O’Brien explains in Science in 5.
This policy brief draws from the latest evidence on the impact of vaccination program start date and vaccine rollout rates on health benefits. The objective is to support policymakers on decisions to procure COVID-19 vaccines and roll out vaccination programmes in countries, especially those
where ...large proportions of the population remain unvaccinated.
more
first issued 18 August 2022
Overview
The aim of this guide is to support national immunization programme managers and others responsible for implementing human rabies vaccine programmes to:
inform policy discussions and operational planning for introducing or expanding rabies post-exposure prophylaxis (PEP) into a nationa...l immunization programme (e.g. through the national immunization programme, or other programmes); and
highlight considerations specific to rabies PEP for integration into existing systems, including for implementation, and monitoring and evaluation.
While the guide is mainly intended for programme managers and focuses on human vaccination, complementary animal health measures are highlighted where relevant given the zoonotic nature of rabies.
The guide was developed collaboratively with input from technical experts in rabies and immunization, vaccines and biologicals.
more